Inavolisib
About
Therapy type: Targeted therapy
Therapy strategy: PI3K/AKT/mTOR inhibition
Mappings
NCI Thesaurus: Inavolisib (ncit:C132166)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive, HER2-negative, PIK3CA somatic variants | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| Sensitivity (+) | HER2-negative, PIK3CA somatic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| Sensitivity (+) | ER positive, HER2-negative, PIK3CA somatic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| Sensitivity (+) | ER positive, HER2-negative, PIK3CA somatic variants | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| Sensitivity (+) | HER2-negative, PIK3CA somatic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| Sensitivity (+) | ER positive, HER2-negative, PIK3CA somatic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib |